Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MELBOURNE, AUSTRALIA--(Marketwired - Aug 15, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced further positive results...
-
MELBOURNE, AUSTRALIA--(Marketwired - Aug 9, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, announced today that the Company will...
-
MELBOURNE, AUSTRALIA--(Marketwired - Aug 7, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced that the Company will be...
-
MELBOURNE, AUSTRALIA--(Marketwired - Jul 6, 2017) - Opthea Limited (ASX: OPT) Composition of Matter and Method of Use claims Patent coverage for OPT-302...
-
MELBOURNE, AUSTRALIA--(Marketwired - Apr 28, 2017) - Opthea Limited (ASX: OPT) ("Opthea"), a developer of novel biologic therapies for the treatment of eye diseases, announced today the completion...
-
MELBOURNE, AUSTRALIA--(Marketwired - Apr 2, 2017) - Opthea Limited (ASX: OPT) Live webcast with presentation slides: https://www.webcaster4.com/Webcast/Page/1668/20456 or ...
-
MELBOURNE, AUSTRALIA--(Marketwired - Mar 31, 2017) - Opthea Limited (ASX : OPT), Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, will host a conference...
-
MELBOURNE, AUSTRALIA--(Marketwired - Mar 20, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, has concluded positive European scientific...
-
MELBOURNE, AUSTRALIA--(Marketwired - Mar 8, 2017) - Opthea Limited (ASX: OPT) -- Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, has completed a Type C...
-
MELBOURNE, AUSTRALIA--(Marketwired - Nov 21, 2016) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, has completed patient enrolment in the...